Luis Pacheco-Figueiredo
Overview
Explore the profile of Luis Pacheco-Figueiredo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramos P, Bras J, Dias C, Bessa-Goncalves M, Botelho F, Silva J, et al.
J Urol
. 2024 Nov;
213(3):304-312.
PMID: 39561374
Purpose: Alternative, noninvasive, cost-effective methods to complement or serve as substitutes to current standard-of-care (SOC) procedures in nonmuscle-invasive bladder cancer (NMIBC) follow-up are needed. Uromonitor is a urine biomarker test...
2.
Meireles S, Dias C, Martins D, Marques A, Dias N, Pacheco-Figueiredo L, et al.
Biomedicines
. 2024 Sep;
12(9).
PMID: 39335667
Background: Molecular profiling in upper tract urothelial carcinoma (UTUC) with synchronous or metachronous urothelial bladder cancer (UBC) is scarce. We intended to assess immunohistochemical (IHC) and genetic differences between UTUC-only...
3.
Botelho F, Braga I, Leao R, Teves F, Dias J, Rodrigues F, et al.
Clin Genitourin Cancer
. 2024 Aug;
22(6):102169.
PMID: 39153249
Introduction And Objectives: New drugs for metastatic castrate resistant prostate cancer (mCRPC) were approved, first in the pos-docetaxel and then in the pre-docetaxel setting. We aim to assess the real...
4.
Ramos P, Mateus A, Manso M, Botelho F, Silva A, Silva J, et al.
Urol Oncol
. 2024 Jan;
42(5):161.e1-161.e8.
PMID: 38267300
Introduction: Bladder cancer (BC) is an increasingly frequent malignancy worldwide. Several variant histologies (VH) have been described in BC with a distinct clinical behavior. Objectives: This study aims to assess...
5.
Braga R, Araujo N, Costa A, Lopes C, Silva I, Correia R, et al.
Eur J Cancer Prev
. 2023 Nov;
33(3):243-251.
PMID: 37997910
Patient characteristics may influence access and acceptance of Prostate Specific Antigen test, and therefore, the timing of prostate cancer (PCa) diagnosis. A group of 361 patients from a cohort (n ...
6.
Botelho F, Lopes R, Pina F, Silva C, Pacheco-Figueiredo L, Lunet N
Sci Rep
. 2023 Nov;
13(1):19362.
PMID: 37938598
Different treatment options exist for localized prostate cancer. Treatments performed in high-volume hospitals are associated with better results. Our objective was to describe time trends in prostate cancer treatments in...
7.
Manso M, Botelho F, Bulhoes C, Cruz F, Pacheco-Figueiredo L
World J Urol
. 2023 Oct;
41(12):3657-3662.
PMID: 37898575
Purpose: Urinary incontinence (UI) is a common condition in women. The aim of this study is to analyze women with self-reported UI, focusing on socio-demographic data, health-related conditions and comorbidities,...
8.
Duarte V, Araujo N, Lopes C, Costa A, Ferreira A, Carneiro F, et al.
Int J Environ Res Public Health
. 2022 Jul;
19(15).
PMID: 35897487
Prostate cancer (PCa) is the most prevalent among men, and psychological symptoms may affect many patients. This study aims to describe the prevalence of probable anxiety and depression before PCa...
9.
Araujo N, Costa A, Lopes C, Lopes-Conceicao L, Ferreira A, Carneiro F, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267663
Cognitive impairment is common among patients with different types of cancer, even before cancer treatment, but no data were reported among patients with prostate cancer (PCa), who may be at...
10.
Beyer K, Moris L, Lardas M, Omar M, Healey J, Tripathee S, et al.
Eur Urol
. 2022 Feb;
81(5):503-514.
PMID: 35184906
Context: Harmonisation of outcome reporting and definitions for clinical trials and routine patient records can enable health care systems to provide more efficient outcome-driven and patient-centred interventions. We report on...